Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common cause of end-stage renal failure and the causative condition in approximately 8% of patients requiring renal replacement therapy in Europe. According to the latest epidemiological data in Italy, about 25,000 individuals are affected by ADPKD. In February 2015, the European Medicines Agency (EMA) approved the use of tolvaptan (JINARC®) for the treatment of ADPKD. Tolvaptan is a selective antagonist for the V2 receptor of vasopressin. It induces the reduction of renal cyst size and kidney volume; furthermore, it restrains cystic cell proliferation. TEMPO 3:4 is a large phase III study that demonstrated the clinical efficacy of tolvaptan in reducing renal volume and slowing renal function loss. The TEMPO 4:4 extension study evaluated for a further two years tolvaptan's safety features and efficacy in patients previously enrolled in TEMPO 3:4. The safety profile emerging from TEMPO 4:4 confirmed the safety and tolerability of this molecule. The most significant clinical safety issue concerns liver toxicity; this occurs in less than 4% of subjects and requires specific monitoring. Post hoc analysis adjusted for major confounders suggested the ability of tolvaptan to retain its therapeutic efficacy even in the extension period. Tolvaptan is the first molecule with proven efficacy in ADPKD; in view of the potential toxicity and the significant aquaretic effect, which reduces the patient's quality of life, the treatment should be directed to a selected population with evidence of rapidly progressive disease.

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease / Magistroni, Riccardo. - In: GIORNALE DI TECNICHE NEFROLOGICHE & DIALITICHE. - ISSN 0394-9362. - 29:2(2017), pp. 80-84-84. [10.5301/GTND.2017.17029]

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease

Magistroni, Riccardo
2017

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the fourth most common cause of end-stage renal failure and the causative condition in approximately 8% of patients requiring renal replacement therapy in Europe. According to the latest epidemiological data in Italy, about 25,000 individuals are affected by ADPKD. In February 2015, the European Medicines Agency (EMA) approved the use of tolvaptan (JINARC®) for the treatment of ADPKD. Tolvaptan is a selective antagonist for the V2 receptor of vasopressin. It induces the reduction of renal cyst size and kidney volume; furthermore, it restrains cystic cell proliferation. TEMPO 3:4 is a large phase III study that demonstrated the clinical efficacy of tolvaptan in reducing renal volume and slowing renal function loss. The TEMPO 4:4 extension study evaluated for a further two years tolvaptan's safety features and efficacy in patients previously enrolled in TEMPO 3:4. The safety profile emerging from TEMPO 4:4 confirmed the safety and tolerability of this molecule. The most significant clinical safety issue concerns liver toxicity; this occurs in less than 4% of subjects and requires specific monitoring. Post hoc analysis adjusted for major confounders suggested the ability of tolvaptan to retain its therapeutic efficacy even in the extension period. Tolvaptan is the first molecule with proven efficacy in ADPKD; in view of the potential toxicity and the significant aquaretic effect, which reduces the patient's quality of life, the treatment should be directed to a selected population with evidence of rapidly progressive disease.
2017
13-mar-2018
29
2
80-84
84
Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease / Magistroni, Riccardo. - In: GIORNALE DI TECNICHE NEFROLOGICHE & DIALITICHE. - ISSN 0394-9362. - 29:2(2017), pp. 80-84-84. [10.5301/GTND.2017.17029]
Magistroni, Riccardo
File in questo prodotto:
File Dimensione Formato  
GTND-17-0028.pdf

Open access

Descrizione: post prints pdf
Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 190.14 kB
Formato Adobe PDF
190.14 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1164369
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact